Metacrine Raises $36M

San Diego-based Metacrine, a biotechnology company which is targeting the treatment of metabolic disease, says it has raised $36M in a Series A funding. The funding came from Arch Venture Partners, EcoR1 Capital, Polaris Partners and venBio. Metacrine has licensed technology from Evans and the howard Hughes Medical Institute. As part of the funding, Metacrine said it has named Neil McDonnell as its CEO; McDonnell was previously Senior Vice President and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.